Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+63.3%
5Y CAGR+99.2%
Year-over-Year Change
Selling, general, and administrative expenses
3Y CAGR
+63.3%/yr
vs +33.6%/yr prior
5Y CAGR
+99.2%/yr
Recent deceleration
Acceleration
+29.6pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
31.4x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $33.80M | +42.2% |
| 2024 | $23.78M | +25.4% |
| 2023 | $18.95M | +144.0% |
| 2022 | $7.77M | +81.2% |
| 2021 | $4.29M | +297.8% |
| 2020 | $1.08M | -78.8% |
| 2019 | $5.07M | +108.1% |
| 2018 | $2.44M | +147.0% |
| 2017 | $987000.00 | - |